ClearSign Board to expand in size to seven directors

ClearSign Technologies (CLIR) announced that the Company’s Board of Directors has voted to expand in size from five to seven directors and it appointed Anthony DiGiandomenico and Lou Basenese to fill such newly created vacancies and to serve as members of the Board, effective as of May 22. Further, on May 27 David M. Maley, a member of the Board, notified the Company that he will not stand for re-election upon the expiration of his term at the Company’s 2025 annual meeting of stockholders. The Board has not yet determined whether it will reduce its size or nominate a replacement director at this time. DiGiandomenico has been working with and enabling investment into early-stage disruptive technologies for most of his career. He has worked alongside a wide range of companies in biotechnology, medical devices, high technology, and renewable energy spaces. DiGiandomenico currently serves as the Chief of Transactions and director of MDB Capital Holdings (MDBH), a broker-dealer and financial advisory firm based in Dallas, Texas, which he co-founded in 1997 as MDB Capital Group. Previously, he has served on the board of directors of Provention Bio a developer of multiple drug therapies, from January 2017 until May 2020 and the board of directors of Cue Biopharma, a company that develops novel biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders, from January 2016 to October 2019. Lou Basenese brings over 25 years of experience in equity research and analysis, investment banking, strategic planning, thought leadership development and communications. Basenese currently serves as Executive Vice President – Market Strategy for Prairie Operating (PROP), a Houston-based publicly traded independent energy company engaged in the development and acquisition of oil and natural gas resources in the US.